SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-23-000006
Filing Date
2023-01-09
Accepted
2023-01-09 08:02:43
Documents
14
Period of Report
2023-01-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20230106.htm   iXBRL 8-K 38021
2 EX-99.1 rvncjan23jpmandcd8-k_ex991.htm EX-99.1 41465
6 logohighres.gif GRAPHIC 38132
  Complete submission text file 0001479290-23-000006.txt   281383

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20230106.xsd EX-101.SCH 1937
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20230106_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20230106_pre.xml EX-101.PRE 12542
8 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20230106_htm.xml XML 11424
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 23516670
SIC: 2834 Pharmaceutical Preparations